Mr Mrs Miss Ms Dr Other

Dr
Alex
Bruce

Trainee Patent Attorney

London Office York Office

Life sciences

Telephone. +44(0) 190 473 2120
Email. abruce@hgf.com
Vcard
Linkedin

Experience

Alex joined HGF in August 2022 as a Trainee Patent Attorney within the Life Sciences group.

He has a broad technical background in the Biosciences with a BSc (Hons) in Biochemistry and Microbiology, MSc in Medical Microbiology, and a PhD in Molecular and Cellular Biology. During his MSc at the University of Manchester, he carried out research on novel drugs to treat Tuberculosis, and was awarded the WWC Topley Prize for obtaining the highest overall marks in his written examinations.

Following this, he carried out doctoral research at the University of Leeds investigating the mechanical mechanisms of Staphylococcus aureus biofilm formation on the molecular scale.

In 2023, Alex obtained his Postgraduate Certificate in Intellectual Property from Bournemouth University.

Alex has a keen interest in Biochemistry, Biotechnology, Molecular Biology, and Microbiology.

Specialisms

Industries

Services

Qualifications

Trainee

BSC

BSc (Hons) in Biochemistry and Microbiology

MSC

MSc in Medical Microbiology

PHD

PhD in Molecular and Cellular Biology

POSTGRADUATE DIPLOMA OR CERTIFICATE

PG Cert Intellectual Property

Recognition

WWC Topley Prize (2017)

This prize is awarded each year to the MSc Medical Microbiology student with the highest overall marks (above distinction level) at the University of Manchester

View recognition online

Download recognition PDF

Publications

A leading case - beware sequence errors in patent claims

View publication online

Exam Success at HGF!

View publication online

Collagen-like Motifs of SasG: A Novel Fold for Protein Mechanical Strength

View publication online

Download publication PDF

Conferences: 2022

11-10-2022

HGF CPD Conference 2022

Attended

Related News

Office Closed Dates December 2025 / January 2026

HGF Office Closed Dates December 2025 / January 2026   UK Thursday 25 and Friday 26 December 2025 CLOSED Thursday 1 January 2026* CLOSED * Friday 2 January 2026 – …

Read article

PRESS RELEASE – HGF strengthens European presence with three new Partners in France and Germany

HGF is pleased to announce the arrival of three new partners, further strengthening its European presence. Two partners will be joining the firm’s fast-growing French practice, and one will join …

Read article

The EPO Board of Appeal comments on the scope of the morality exclusion from patentability

The recent decision, T1553/22 of the Board of Appeal required the Board to consider the scope of the exclusions from patentability under Article 53(a) EPC. The invention in this case …

Read article

Agritech Thymes: Unlocking the Soil Microbiome: Driving Agritech Innovation in the UK

The UK offers an ideal platform for harnessing the untapped potential of soil and plant microorganisms. Although much of my professional experience has focused on the human microbiome, I have …

Read article

The Antibody Series #1 | Quality Characteristics (CQAs) in Antibody Claims: When the Test Method Can Remain Outside the Claim

Introduction Therapeutic antibodies are at the heart of innovations in biotechnology and healthcare. With increasing regulatory requirements and quality expectations, critical quality attributes (CQAs) are becoming essential in the drafting …

Read article
Event - 3rd February 2026

HGF Brand & Design Conference 2026

Join us on 3rd February 2026 for HGF’s Brand & Design Conference, the must attend event for in-house legal teams, brand leaders, creatives, and innovators shaping the future of IP. …

Event details

EU Agrees on NGT Plant Regulation: What It Means for Patents and Licensing

The European Parliament and Council have reached a provisional agreement for plants developed using New Genomic Techniques (NGTs) – below we summarise the main points and set out the requirements …

Read article
See all updates

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.

Contact us